At the time of writing, United Therapeutics Corp [UTHR] stock is trading at $438.66, down -1.52%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The UTHR shares have gain 4.18% over the last week, with a monthly amount drifted -3.18%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
United Therapeutics Corp [NASDAQ: UTHR] stock has seen the most recent analyst activity on October 20, 2025, when Wells Fargo initiated its Underweight rating and assigned the stock a price target of $414. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on September 26, 2025, and set its price target to $569. On June 02, 2025, Cantor Fitzgerald initiated with an Overweight rating and assigned a price target of $405 on the stock. Wells Fargo downgraded its rating to a Equal Weight. BofA Securities upgraded its rating to a Neutral but $314 remained the price target by the analyst firm on April 21, 2025. Morgan Stanley downgraded its rating to Equal-Weight for this stock on July 11, 2024, and upped its price target to $321. In a note dated February 12, 2024, Goldman upgraded a Neutral rating on this stock and boosted its target price from $213 to $215.
For the past year, the stock price of United Therapeutics Corp fluctuated between $266.98 and $479.50. Currently, Wall Street analysts expect the stock to reach $538 within the next 12 months. United Therapeutics Corp [NASDAQ: UTHR] shares were valued at $438.66 at the most recent close of the market. An investor can expect a potential return of 22.65% based on the average UTHR price forecast.
Analyzing the UTHR fundamentals
According to United Therapeutics Corp [NASDAQ:UTHR], the company’s sales were 3.13B for trailing twelve months, which represents an 6.76% jump. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.48%, Pretax Profit Margin comes in at 0.53%, and Net Profit Margin reading is 0.41%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.19 and Total Capital is 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 431.77 points at the first support level, and at 424.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 445.77, and for the 2nd resistance point, it is at 452.89.
Ratios To Look Out For
It is important to note that United Therapeutics Corp [NASDAQ:UTHR] has a current ratio of 6.40. As well, the Quick Ratio is 6.07, while the Cash Ratio is 2.45. Considering the valuation of this stock, the price to sales ratio is 6.04, the price to book ratio is 2.86 and price to earnings (TTM) ratio is 16.63.
Transactions by insiders
Recent insider trading involved Michael Benkowitz, Officer, that happened on Nov 03 ’25 when 90000.0 shares were purchased. FOUNDER, CHAIRPERSON, AND CHIE, ROTHBLATT MARTINE A completed a deal on Nov 03 ’25 to buy 4000.0 shares. Meanwhile, FOUNDER, CHAIRPERSON, AND CHIE ROTHBLATT MARTINE A bought 4000.0 shares on Oct 31 ’25.
